Overview
- The study published in Nature Medicine reported that PANXEON detected about 86 to 87 percent of stage I–II pancreatic ductal adenocarcinomas in an international observational dataset.
- PANXEON integrates three biomarkers—CA19‑9 plus a 13‑microRNA signature measured in plasma and exosomes—and uses an XGBoost AI model to produce a composite risk score.
- The analysis, which appeared Sept. 16, 2026, examined 1,757 plasma samples from 1,649 people recruited across sites in the United States, Japan, Italy and South Korea.
- Specificity was acceptable in low‑risk controls (3.2% false positives) but was lower in high‑risk controls (15.6% false positives), so a positive result is described by investigators as a risk signal that should trigger further imaging or evaluation rather than immediate surgery.
- The test also identified high‑grade dysplasia in cyst patients (64.3% sensitivity) and showed promise for tracking treatment response, but authors stress small surgical cohorts, demographic gaps and unknown lead time require prospective longitudinal trials to determine if PANXEON improves resectability or survival.